Key result
Extended ablation did not reduce arrhythmia recurrence compared with limited ablation in patients with pulmonary hypertension and supraventricular arrhythmias.
Why the study?
It was unknown whether extensive bi-atrial substrate ablation is superior to clinical arrhythmia ablation alone for supraventricular arrhythmias in pulmonary hypertension.
Does extensive substrate-based ablation reduce arrhythmia recurrence in patients with pulmonary hypertension and supraventricular arrhythmias compared to clinical arrhythmia ablation alone?
RCT (n=77)
1:1
Yes
Does extensive substrate-based ablation reduce arrhythmia recurrence in patients with pulmonary hypertension and supraventricular arrhythmias compared to clinical arrhythmia ablation alone?
Extensive substrate-based ablation does not significantly reduce arrhythmia recurrence compared to limited clinical arrhythmia ablation in patients with pulmonary hypertension and supraventricular arrhythmias.
Answers are grounded in this paper and cite their sources.
Extended ablation adds no benefit over limited ablation here; challenges routine substrate modification in pulmonary hypertension.
AIMS: Atrial fibrillation (AF), typical atrial flutter (AFL), and other atrial tachycardias (ATs) are common in patients with pulmonary hypertension. Frequently, several supraventricular arrhythmias are successively observed in individual patients. We investigated the hypothesis of whether more extensive radiofrequency catheter ablation of the bi-atrial arrhythmogenic substrate instead of clinical arrhythmia ablation alone results in superior clinical outcomes in patients with pulmonary arterial hypertension (PH) and supraventricular arrhythmias. METHODS AND RESULTS: Patients with combined post- and pre-capillary or isolated pre-capillary PH and supraventricular arrhythmia indicated to catheter ablation were enrolled in three centres and randomized 1:1 into two parallel treatment arms. Patients underwent either clinical arrhythmia ablation only (Limited ablation group) or clinical arrhythmia plus substrate-based ablation (Extended ablation group). The primary endpoint was arrhythmia recurrence >30 s without antiarrhythmic drugs after the 3-month blanking period. A total of 77 patients (mean age 67 ± 10 years; 41 males) were enrolled. The presumable clinical arrhythmia was AF in 38 and AT in 36 patients, including typical AFL in 23 patients. During the median follow-up period of 13 (interquartile range: 12; 19) months, the primary endpoint occurred in 15 patients (42%) vs. 17 patients (45%) in the Extended vs. Limited ablation group (hazard ratio: 0.97, 95% confidence interval: 0.49-2.0). There was no excess of procedural complications and clinical follow-up events including an all-cause death in the Extended ablation group. CONCLUSION: Extensive ablation, compared with a limited approach, was not beneficial in terms of arrhythmia recurrence in patients with AF/AT and PH. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov; NCT04053361.
No takes yet. Share an insight, caveat, or question.
Havránek et al. (2023) conducted an RCT in Pulmonary hypertension and supraventricular arrhythmias (n=77). Extended ablation (clinical arrhythmia plus substrate-based ablation) vs. Limited ablation (clinical arrhythmia ablation only) was evaluated on Arrhythmia recurrence >30 s without antiarrhythmic drugs after the 3-month blanking period (HR 0.97, 95% CI 0.49-2.0). Extended ablation did not reduce arrhythmia recurrence compared with limited ablation in patients with pulmonary hypertension and supraventricular arrhythmias.
Synapse has enriched 10 related papers. Consider them for comparative context: